Jeena Sikho Lifecare Limited has officially informed the stock exchanges regarding its strategic proposal to establish a new Day Care Clinic in Ayodhya, Uttar Pradesh. This initiative is a part of the company’s ongoing efforts to scale its holistic healthcare network and provide quality Panchakarma services to a broader patient base. The disclosure was made on June 11, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The proposed facility will be set up at Ram Path Road, Ayodhya, covering an estimated area of approximately 2,300 square feet. The company expects to commence operations at this clinic by August 2026. This expansion demands an estimated capital investment of approximately Rs. 50 Lakhs, which will be entirely funded through the company’s internal finance and owned funds, indicating a strong cash-flow position and no reliance on external debt for this project.

PDF+ 2

Jeena Sikho Lifecare Limited is a prominent player in the Indian healthcare industry, widely recognized for its “Shuddhi Ayurveda” brand, which offers an array of traditional Ayurvedic remedies, wellness products, and healthcare services. The company operates a vast network of over 120 Ayurveda clinics and hospitals across the country. Throughout 2025, the company aggressively executed its north India healthcare expansion, notably upgrading its existing network facilities across Punjab and Haryana, while executing massive infrastructural additions.

In terms of financial performance during the periods leading up to this expansion, Jeena Sikho reported a spectacular trajectory in 2025. For the financial year ending March 31, 2025, the company generated a stellar annual revenue of Rs. 475 Crores. This robust top-line growth was supported by aggressive patient volume expansion across both its In-Patient Department (IPD) and Out-Patient Department (OPD) segments. The corporate growth has been primarily driven by its promoter-led management, with Managing Director Manish Grover steering its strategic shift toward high-margin private business segments and successful over-the-counter (OTC) medicine launches.